Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients.
This study reports the results of an evaluation of the effectiveness and tolerability of rifaximin, an intestinal topical antibiotic. It was administered using a nasogastric tube in patients with severe enterocolitis and bacterial superinfections causing intestinal inflammatory diseases and portosystemic encephalopathy. The drug proved highly effective clinically and produced neither local nor systemic side-effects.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000641:Ammonia / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000382:microbiology; D007441:Intubation, Gastrointestinal; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000009:adverse effects / Q000627:therapeutic use*; D000078262:Rifaximin
D012294:Rifamycins; D000641:Ammonia; D000078262:Rifaximin